VectorY Therapeutics
Amsterdam, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $129M
Overview
Pioneering vectorized antibody gene therapies for neurodegenerative diseases.
Neuroscience
Technology Platform
A proprietary platform designing AAV vectors to deliver genes encoding therapeutic antibodies for sustained, localized expression in the central nervous system.
Funding History
1Total raised:$129M
Series A$129M
Opportunities
Potential to create transformative, one-time treatments for devastating neurodegenerative diseases with high unmet need.
Risk Factors
Significant technical risks include immune response to vectors, controlling antibody expression levels, and demonstrating efficacy in complex neurodegenerative conditions.
Competitive Landscape
Competes with other CNS gene therapy firms and biologics developers, but is differentiated by its focus on vectorized antibodies for neurodegeneration.